



Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

### Complete if Known

Application Number	09/606,909
Filing Date	June 29, 2000
First Named Inventor	PETTIS <i>et al.</i>
Group Art Unit	3748
Examiner Name	Binh Q. TRAN
Attorney Docket Number	P-4901

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
PG	AA	2,619,962		Rosenthal	12/02/1952	
PG	AB	3,814,097		Ganderton et al.	06/04/1974	
PG	AC	3,964,482		Gerstel et al.	06/22/1976	
PG	AD	4,270,537		Romaine	06/02/1981	
PG	AE	4,592,753		Panoz	06/03/1986	
PG	AF	5,003,987		Grinwald	04/02/1991	
PG	AG	5,098,389		Cappucci	03/24/1992	
PG	AH	5,156,591		Gross et al.	10/20/1992	
PG	AI	5,250,023		Lee et al.	10/05/1993	
PG	AJ	5,279,544		Gross et al.	01/18/1994	
PG	AK	5,417,662		Hjertman et al.	05/23/1995	
PG	AL	5,527,288		Gross et al.	06/18/1996	
PG	AM	5,591,139		Lin et al.	01/07/1997	
PG	AN	5,801,057		Smart et al.	09/01/1998	
PG	AO	5,820,622		Gross et al.	10/13/1998	
PG	AP	5,848,991		Gross et al.	12/15/1998	
PG	AQ	5,876,582		Frazier	03/02/1999	
PG	AR	5,879,326		Godshall et al.	03/09/1999	
PG	AS	5,928,207		Pisano et al.	07/27/1999	
PG	AT	5,957,895		Sage et al.	09/28/1999	
PG	AU	5,997,501		Gross et al.	12/07/1999	
PG	AV	6,099,504		Gross et al.	08/08/2000	
PG	AW	6,334,856	B1	Allen et al.	01/01/2002	
PG	AX	6,346,095	B1	Gross et al.	02/12/2002	

RECEIVED  
NOV 13 2002  
TECHNOLOGY CENTER B3706

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
PG	AY	CA	2 349 431		Canada	05/25/2000		
PG	AZ	EP	1 086 718	A1	Europe	03/28/2001		
PG	BA	EP	1 086 719	A1	Europe	03/28/2001		
PG	BB	EP	1 088 642	A1	Europe	04/04/2001		
PG	BC	EP	1 092 444	A1	Europe	04/18/2001		
PG	BD	WO	96/17648		PCT	06/13/1996		
PG	BE	WO	96/37155		PCT	11/28/1996		
PG	BF	WO	96/37256		PCT	11/28/1996		
PG	BG	WO	99/43350		PCT	09/02/1999		
PG	BH	WO	99/64580		PCT	12/16/1999		
PG	BI	WO	00/67647		PCT	11/16/2000		
PG	BJ	WO	00/74763	A2	PCT	12/14/2000		
PG	BK	WO	02/11669	A2	PCT	02/14/2002		

/Phillip Gray/  
2/5/2013

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

## Complete if Known

Application Number	09/606,909
Filing Date	June 29, 2000
First Named Inventor	PETTIS <i>et al.</i>
Group Art Unit	3748
Examiner Name	Binh Q. TRAN
Attorney Docket Number	P-4901

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PG	BL	E. AUTRET <i>et al.</i> , Therapie 1991, 46 : 5-8.	
PG	BM	BRESSOLLE <i>et al.</i> , "A Weibull Distribution Model for Intradermal Administration of Ceftazidime", Journal of Pharmaceutical Sciences, Vol. 82, No. 11, November 1993, pps. 1175-1178.	
PG	BN	HENRY <i>et al.</i> , "Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery", Journal of Pharmaceutical Sciences, Vol. 87, No. 8, August 1998, pps. 922-925.	
PG	BO	KAUSHIK <i>et al.</i> , "Transdermal Protein Delivery Using Microfabricated Microneedles", Oct/Nov 1999 (1 page).	
PG	BP	BURKOTH <i>et al.</i> , "Transdermal and Transmucosal Powered Drug Delivery", Critical Review™ in Therapeutic Drug Carrier Systems, 16 (4), (1999), pps. 331-384.	
PG	BQ	MCALLISTER <i>et al.</i> , "Three-Dimensional Hollow Microneedle and Microtube Arrays", Conference: Solid-State Sensors and Actuators Transducers-Conference, 1999; 10 <sup>th</sup> ; Vol. 12, pp 1098-1103.	
PG	BR	MCALLISTER <i>et al.</i> , "Solid and Hollow Microneedles for Transdermal Protein Delivery", Proceed. Int'l. Symp. Control. Rel. Bioact. Mater., 26 (Revised July 1999) Controlled Release Society, Inc. pp. 192-193	
PG	BS	SEBASTIEN <i>et al.</i> , "Microfabricated Needles: A Novel Approach to Transdermal Drug Delivery", Journal of Pharmaceutical Sciences, Vol. 87, No. 8, August 1998, pp. 922-925	

RECEIVED

NOV 13 2002

TECHNOLOGY CENTER R3700  
TECHNOLOGY CENTER R3700

Examiner Signature	/Phillip Gray/	Date Considered	2/5/2013
--------------------	----------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DEC 18 2002  
PATENT & TRADEMARK OFFICE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	1	of	4
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	09/606,909
<b>Filing Date</b>	June 29, 2000
<b>First Named Inventor</b>	Pettis, et al.
<b>Art Unit</b>	3748
<b>Examiner Name</b>	Binh Q. Tran
<b>Attorney Docket Number</b>	P-4901

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	76
		Office <sup>3</sup>	Number <sup>4</sup>	Kind <sup>5</sup> (if known)				
B5	AB	EP	0 429 842	B1	08/28/1996	Europe	—	
↓	AC	WO	94/23777		10/27/1994	PCT	RECEIVED	
↓	AD	WO	97/21457		6/19/1997	PCT		
	AE	WO	00/09186		2/24/2000	PCT		
							DEC 23 2002	
							TECHNOLOGY CENTER R3700	

Examiner  
Signature

BINH TRAN

Date  
Considered


01/05/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

\* The reference has been cited in PTO-892.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	09/606,909
			Filing Date	June 29, 2000
			First Named Inventor	Pettis, et al.
			Group Art Unit	3748
			Examiner Name	Binh Q. Tran
			Attorney Docket Number	P-4901
Sheet	2	of	4	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
BT	AF	AGRAWAL, et al., "Pharmacokinetics, Biodistribution, and Stability of Oligodeoxynucleotide Phosphorothioates in Mice", Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 7595-7599, September 1991 Medical Sciences		
	AG	AUTRET, et al., "Comparison of Pharmacokinetics and tolerance of Calcitonine administered by Intradermal or Subcutaneous Route", Fundamental Clinical Pharmacology, Vol. 3, No. 2, pp 170-171, 1989		
	AH	BENONI, et al., "Distribution of Cefazidime in Ascitic Fluid", Antimicrobial Agents and Chemotherapy, Vol. 25, No. 6, June 1984, pp. 760-763		
	AI	BICKERS, et al., editors, "Clinical Pharmacology of Skin Disease", pp. 57-90, Churchill Livingstone, Inc., 1984		
	AJ	BOCCI, et al., "The Lymphatic Route. IV. Pharmacokinetics of Human Recombinant Interferon a2 and Natural Interferon B Administered Intradermally in Rabbits", International Journal of Pharmaceutics, 32, 1986, pp. 103-110 Elsevier Science Publishers B.V. (Biomedical Division)		
	AK	CALLEN, "Intralesional Corticosteroids", Journal of the American Academy of Dermatology, University of Louisville School of Medicine, pp. 149-151, 1981		
	AL	COSSUM, et al., "Disposition of the C-Labeled Phosphorothioate Oligonucleotide ISIS 2105 after Intravenous Administration to Rats", The Journal of Pharmacology and Experimental Therapeutics, pp. 1181-1190, Vol. 267, No. 3, 1993		
	AM	COSSUM, et al., "Pharmacokinetics of C-Labeled Phosphorothioate Oligonucleotide, ISIS 2105 after Administration to Rats", The Journal of Pharmacology and Experimental Therapeutics, pp. 89-94, Vol. 269, No. 1, 1994		
	AN	CROOKE, et al., "A Pharmacokinetic Evaluation of C-Labeled Afovirsen Sodium in Patients with Genital Warts", Clinical Pharmacology & Therapeutics, pp. 641-646, Vol. 56, No. 6, Part 1, December 1994		
	AO	FIROOZ, et al., "Benefits and Risks of Intralesional Corticosteroid Injection in the Treatment of Dermatological Diseases", pp. 363-370, Vol. 20, No. 5, Clinical and Experimental Dermatology, Blackwell Science Ltd, September 1995		
✓	AP	GOODARZI, et al., "Organ Distribution and Stability of Phosphorothioated Oligodeoxyribonucleotides in Mice", Biopharmaceutics & Drug Disposition, pp. 221-227, Vol. 13, No. 3, John Wiley & Sons, Ltd, April 1992		

Examiner Signature	BINH TRAN	Date Considered	01/05/03
--------------------	-----------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

### Complete if Known

Application Number	09/606,909
Filing Date	June 29, 2000
First Named Inventor	Pettis, et al.
Group Art Unit	3748
Examiner Name	Binh Q. Tran
Attorney Docket Number	P-4901

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BT	AQ	HAYNES, et al., "Ultra-long-duration Local Anesthesia Produced by Injection of Lecithin-coated Methoxyflurane Microdroplets", Anesthesiology, Vol. 63, No. 5, pp. 490-499, Nov. 1985	
	AR	JAKOBSON, et al., "Variations in the Blood Concentration of 1, 1,2-Trichloroethane by Percutaneous Absorption and Other Routes of Administration in the Guinea Pig", Vol. 41, No. 5, pp.497-506, Acta Pharmacologica et Toxicologica, November 1977	
	AS	JARRATT, et al., "The Effects of Intradermal Steroids on the Pituitary-Adrenal Axis and the Skin", The Journal of Investigative Dermatology, Vol. 62, No. 4, pp. 463-466, 1974	
	AT	KIRKPATRICK, et al., "Local Anesthetic Efficacy of Methoxyflurane Microdroplets in Man", Vol. 67, No. 3A, Anesthesiology, September 1987	
	AU	LEROY, et al., "Pharmacokinetics of Cefazidime in Normal and Uremic Subjects", Antimicrobial Agents and Chemotherapy, Vol. 25, No. 5, pp. 638-642, May 1984	
	AV	MCGUGAN, et al., "Adrenal Suppression from Intradermal Triamcinolone", The Journal of Investigative Dermatology, Vol. 40, pp. 271-272, Baltimore, MD., 1963	
	AW	SCOTT, et al., "Toxicity of Interferon", Vol. 282, pp. 1345-1348, British Medical Journal, April 25, 1981	
	AX	SUPERSAXO, et al., "Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application", Pharmaceutical Research, Vol. 5, No. 8, pp. 472-476, August 1988	
	AY	SUTHEREST, "Treatment of Pruritus Vulvae by Multiple Intradermal Injections of Alcohol. A Double-Blind Study, Vol. 86, pp. 371-373, British Journal of Obstetrics and Gynecology, May 1979	
	AZ	WARD, et al., "Pruritus Vulvae: Treatment by Multiple Intradermal Alcohol Injections", Vol. 93, No. 2, pp. 201-204, British Journal of Dermatology, August 1975	
✓	BA	WU, et al., "Pharmacokinetics of Methoxyflurane after its Intra-Dermal Injection as Lecithin-Coated Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.	

RECEIVED

DEC 23 2002

Examiner  
Signature

BINH TRAN

Date  
Considered

TECHNOLOGY CENTER R0700  
01/05/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

